Medication use in breast cancer survivors compared to midlife women

Julie Otte, Todd Skaar, Jingwei Wu, Menggang Yu, Kristin Ryker, Debra S. Burns, Janet Carpenter

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Many breast cancer survivors (BCS) take multiple medications for health problems associated with the treated cancer and other noncancer comorbidities. However, there is no published, large-scale descriptive evaluation of medication use in BCS compared to midlife women. The purpose of this study was (1) to compare the number and types of prescription medications and over-the-counter medications between BCS and midlife women without cancer and (2) to assess possible drug-drug interactions by evaluating the cytochrome P450 isoform properties of medications (inductors and inhibitors) in both groups. Methods: A cross-sectional, descriptive, comparative design was used. Baseline data from 98 BCS and 138 midlife women without cancer was analyzed from a behavioral intervention trial for menopausal symptoms. Results: BCS were taking significantly more prescription medications and a larger variety of different types of medication classifications (p < 0.05) after controlling for group differences (race, noncancer comorbid conditions, marital status, income, and smoking) in demographics. Twenty-four women were taking at least one medication considered to be a cytochrome P450 isoforms (CYP) inhibitor or inducer capable of clinical drug-drug interactions with no differences in CYP inhibitors or inducers found between groups. Conclusion: BCS are taking a vast array of medications during survivorship. It is unclear if prescription medications are managed by a single healthcare provider or several providers. Clinical implications are to monitor for possible interactions among the various prescription medications, over-the-counter medications, and supplements. Implications for behavioral and biomedical research are that clinical studies need to carefully assess and account for multiple medication uses. Relevance of the study: The findings of this study are relevant to research and practice for both oncology and general practitioners. The importance of assessing medication information provides information about symptom management in individuals surviving cancer. In addition, the potential interaction of drugs impacts efficacy of various treatments and impacts compliance by patients.

Original languageEnglish
Pages (from-to)1827-1833
Number of pages7
JournalSupportive Care in Cancer
Volume21
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Survivors
Breast Neoplasms
Prescriptions
Drug Interactions
Cytochrome P-450 Enzyme System
Protein Isoforms
Neoplasms
Behavioral Research
Marital Status
Patient Compliance
Pharmaceutical Preparations
Health Personnel
General Practitioners
Biomedical Research
Comorbidity
Survival Rate
Smoking
Demography
Health
Research

Keywords

  • Breast cancer survivor
  • Drug interaction
  • Medication use
  • Self-management

ASJC Scopus subject areas

  • Oncology

Cite this

Medication use in breast cancer survivors compared to midlife women. / Otte, Julie; Skaar, Todd; Wu, Jingwei; Yu, Menggang; Ryker, Kristin; Burns, Debra S.; Carpenter, Janet.

In: Supportive Care in Cancer, Vol. 21, No. 7, 07.2013, p. 1827-1833.

Research output: Contribution to journalArticle

Otte, Julie ; Skaar, Todd ; Wu, Jingwei ; Yu, Menggang ; Ryker, Kristin ; Burns, Debra S. ; Carpenter, Janet. / Medication use in breast cancer survivors compared to midlife women. In: Supportive Care in Cancer. 2013 ; Vol. 21, No. 7. pp. 1827-1833.
@article{3cfbe604d138484cb182698fb7bcb8a0,
title = "Medication use in breast cancer survivors compared to midlife women",
abstract = "Purpose: Many breast cancer survivors (BCS) take multiple medications for health problems associated with the treated cancer and other noncancer comorbidities. However, there is no published, large-scale descriptive evaluation of medication use in BCS compared to midlife women. The purpose of this study was (1) to compare the number and types of prescription medications and over-the-counter medications between BCS and midlife women without cancer and (2) to assess possible drug-drug interactions by evaluating the cytochrome P450 isoform properties of medications (inductors and inhibitors) in both groups. Methods: A cross-sectional, descriptive, comparative design was used. Baseline data from 98 BCS and 138 midlife women without cancer was analyzed from a behavioral intervention trial for menopausal symptoms. Results: BCS were taking significantly more prescription medications and a larger variety of different types of medication classifications (p < 0.05) after controlling for group differences (race, noncancer comorbid conditions, marital status, income, and smoking) in demographics. Twenty-four women were taking at least one medication considered to be a cytochrome P450 isoforms (CYP) inhibitor or inducer capable of clinical drug-drug interactions with no differences in CYP inhibitors or inducers found between groups. Conclusion: BCS are taking a vast array of medications during survivorship. It is unclear if prescription medications are managed by a single healthcare provider or several providers. Clinical implications are to monitor for possible interactions among the various prescription medications, over-the-counter medications, and supplements. Implications for behavioral and biomedical research are that clinical studies need to carefully assess and account for multiple medication uses. Relevance of the study: The findings of this study are relevant to research and practice for both oncology and general practitioners. The importance of assessing medication information provides information about symptom management in individuals surviving cancer. In addition, the potential interaction of drugs impacts efficacy of various treatments and impacts compliance by patients.",
keywords = "Breast cancer survivor, Drug interaction, Medication use, Self-management",
author = "Julie Otte and Todd Skaar and Jingwei Wu and Menggang Yu and Kristin Ryker and Burns, {Debra S.} and Janet Carpenter",
year = "2013",
month = "7",
doi = "10.1007/s00520-013-1727-5",
language = "English",
volume = "21",
pages = "1827--1833",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Medication use in breast cancer survivors compared to midlife women

AU - Otte, Julie

AU - Skaar, Todd

AU - Wu, Jingwei

AU - Yu, Menggang

AU - Ryker, Kristin

AU - Burns, Debra S.

AU - Carpenter, Janet

PY - 2013/7

Y1 - 2013/7

N2 - Purpose: Many breast cancer survivors (BCS) take multiple medications for health problems associated with the treated cancer and other noncancer comorbidities. However, there is no published, large-scale descriptive evaluation of medication use in BCS compared to midlife women. The purpose of this study was (1) to compare the number and types of prescription medications and over-the-counter medications between BCS and midlife women without cancer and (2) to assess possible drug-drug interactions by evaluating the cytochrome P450 isoform properties of medications (inductors and inhibitors) in both groups. Methods: A cross-sectional, descriptive, comparative design was used. Baseline data from 98 BCS and 138 midlife women without cancer was analyzed from a behavioral intervention trial for menopausal symptoms. Results: BCS were taking significantly more prescription medications and a larger variety of different types of medication classifications (p < 0.05) after controlling for group differences (race, noncancer comorbid conditions, marital status, income, and smoking) in demographics. Twenty-four women were taking at least one medication considered to be a cytochrome P450 isoforms (CYP) inhibitor or inducer capable of clinical drug-drug interactions with no differences in CYP inhibitors or inducers found between groups. Conclusion: BCS are taking a vast array of medications during survivorship. It is unclear if prescription medications are managed by a single healthcare provider or several providers. Clinical implications are to monitor for possible interactions among the various prescription medications, over-the-counter medications, and supplements. Implications for behavioral and biomedical research are that clinical studies need to carefully assess and account for multiple medication uses. Relevance of the study: The findings of this study are relevant to research and practice for both oncology and general practitioners. The importance of assessing medication information provides information about symptom management in individuals surviving cancer. In addition, the potential interaction of drugs impacts efficacy of various treatments and impacts compliance by patients.

AB - Purpose: Many breast cancer survivors (BCS) take multiple medications for health problems associated with the treated cancer and other noncancer comorbidities. However, there is no published, large-scale descriptive evaluation of medication use in BCS compared to midlife women. The purpose of this study was (1) to compare the number and types of prescription medications and over-the-counter medications between BCS and midlife women without cancer and (2) to assess possible drug-drug interactions by evaluating the cytochrome P450 isoform properties of medications (inductors and inhibitors) in both groups. Methods: A cross-sectional, descriptive, comparative design was used. Baseline data from 98 BCS and 138 midlife women without cancer was analyzed from a behavioral intervention trial for menopausal symptoms. Results: BCS were taking significantly more prescription medications and a larger variety of different types of medication classifications (p < 0.05) after controlling for group differences (race, noncancer comorbid conditions, marital status, income, and smoking) in demographics. Twenty-four women were taking at least one medication considered to be a cytochrome P450 isoforms (CYP) inhibitor or inducer capable of clinical drug-drug interactions with no differences in CYP inhibitors or inducers found between groups. Conclusion: BCS are taking a vast array of medications during survivorship. It is unclear if prescription medications are managed by a single healthcare provider or several providers. Clinical implications are to monitor for possible interactions among the various prescription medications, over-the-counter medications, and supplements. Implications for behavioral and biomedical research are that clinical studies need to carefully assess and account for multiple medication uses. Relevance of the study: The findings of this study are relevant to research and practice for both oncology and general practitioners. The importance of assessing medication information provides information about symptom management in individuals surviving cancer. In addition, the potential interaction of drugs impacts efficacy of various treatments and impacts compliance by patients.

KW - Breast cancer survivor

KW - Drug interaction

KW - Medication use

KW - Self-management

UR - http://www.scopus.com/inward/record.url?scp=84878720544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878720544&partnerID=8YFLogxK

U2 - 10.1007/s00520-013-1727-5

DO - 10.1007/s00520-013-1727-5

M3 - Article

C2 - 23397094

AN - SCOPUS:84878720544

VL - 21

SP - 1827

EP - 1833

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 7

ER -